Environmental Toxins and Alzheimer's Disease: a Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation
- PMID: 38006469
- DOI: 10.1007/s12035-023-03805-x
Environmental Toxins and Alzheimer's Disease: a Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation
Abstract
Alzheimer's disease is a leading cause of mortality worldwide. Inorganic and organic hazards, susceptibility to harmful metals, pesticides, agrochemicals, and air pollution are major environmental concerns. As merely 5% of AD cases are directly inherited indicating that these environmental factors play a major role in disease development. Long-term exposure to environmental toxins is believed to progress neuropathology, which leads to the development of AD. Numerous in-vitro and in-vivo studies have suggested the harmful impact of environmental toxins at cellular and molecular level. Common mechanisms involved in the toxicity of these environmental pollutants include oxidative stress, neuroinflammation, mitochondrial dysfunction, abnormal tau, and APP processing. Increased expression of GSK-3β, BACE-1, TNF-α, and pro-apoptotic molecules like caspases is observed upon exposure to these environmental toxins. In addition, the expression of neurotrophins like BDNF and GAP-43 have been found to be reduced as a result of toxicity. Further, modulation of signaling pathways involving PARP-1, PGC-1α, and MAPK/ERK induced by toxins have been reported to contribute in AD pathogenesis. These pathways are a promising target for developing novel AD therapeutics. Drugs like epigallocatechin-gallate, neflamapimod, salsalate, dexmedetomidine, and atabecestat are in different phases of clinical trials targeting the pathways for possible treatment of AD. This review aims to culminate the correlation between environmental toxicants and AD development. We emphasized upon the signaling pathways involved in the progression of the disease and the therapeutics under clinical trial targeting the altered pathways for possible treatment of AD.
Keywords: Alzheimer’s disease; Environmental pollutants; Heavy metals; MAPK/ERK; PARP; SIRT1.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Apoptosis in Alzheimer's disease: insight into the signaling pathways and therapeutic avenues.Apoptosis. 2023 Aug;28(7-8):943-957. doi: 10.1007/s10495-023-01848-y. Epub 2023 Apr 26. Apoptosis. 2023. PMID: 37186274 Review.
-
[Environmental pollutants and Alzheimer's disease].Sheng Li Xue Bao. 2023 Dec 25;75(6):740-766. Sheng Li Xue Bao. 2023. PMID: 38151341 Review. Chinese.
-
Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.Mol Neurobiol. 2016 Jan;53(1):648-661. doi: 10.1007/s12035-014-9053-6. Epub 2014 Dec 17. Mol Neurobiol. 2016. PMID: 25511446 Free PMC article. Review.
-
Environmental toxins and Alzheimer's disease progression.Neurochem Int. 2020 Dec;141:104852. doi: 10.1016/j.neuint.2020.104852. Epub 2020 Sep 30. Neurochem Int. 2020. PMID: 33010393 Review.
-
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8. Eur J Med Chem. 2019. PMID: 30877973 Review.
Cited by
-
Shedding light on microglial dysregulation in Alzheimer's disease: exploring molecular mechanisms and therapeutic avenues.Inflammopharmacology. 2025 Feb;33(2):679-702. doi: 10.1007/s10787-024-01598-6. Epub 2024 Nov 28. Inflammopharmacology. 2025. PMID: 39609333 Review.
-
Impact of corticoid receptors on Alzheimer's disease: a neuroendocrine perspective.Inflammopharmacology. 2025 May;33(5):2641-2656. doi: 10.1007/s10787-025-01734-w. Epub 2025 Apr 18. Inflammopharmacology. 2025. PMID: 40249479 Review.
-
Resveratrol as a Therapeutic Agent in Alzheimer's Disease: Evidence from Clinical Studies.Nutrients. 2025 Aug 5;17(15):2557. doi: 10.3390/nu17152557. Nutrients. 2025. PMID: 40806141 Free PMC article. Review.
-
Deciphering Molecular and Signaling Pathways of Extracellular Vesicles-Based Therapeutics for Alzheimer's Disease.Mol Neurobiol. 2025 Jul 18. doi: 10.1007/s12035-025-05216-6. Online ahead of print. Mol Neurobiol. 2025. PMID: 40679697 Review.
-
Trends and inequalities in the global burden of alzheimer's disease and other dementias, 1990-2021: a Chinese perspective.BMC Public Health. 2025 Aug 30;25(1):2977. doi: 10.1186/s12889-025-24097-x. BMC Public Health. 2025. PMID: 40885984 Free PMC article.
References
-
- Dhapola R, Sarma P, Medhi B, et al. (2021) Recent advances in molecular pathways and therapeutic implications targeting mitochondrial dysfunction for Alzheimer’s disease. Mol Neurobiol 1–21
-
- Bhatti JS, Kaur S, Mishra J et al (2023) Targeting dynamin-related protein-1 as a potential therapeutic approach for mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys acta Mol basis Dis 1869:166798. https://doi.org/10.1016/j.bbadis.2023.166798 - DOI - PubMed
-
- Nagar P, Sharma P, Dhapola R, et al. (2023) Endoplasmic reticulum stress in Alzheimer’s disease: molecular mechanisms and therapeutic prospects. Life Sci 121983 https://doi.org/10.1016/J.LFS.2023.121983
-
- Beura SK, Dhapola R, Panigrahi AR et al (2023) Antiplatelet drugs: potential therapeutic options for the management of neurodegenerative diseases. Med Res Rev 43:1835–1877. https://doi.org/10.1002/MED.21965 - DOI - PubMed
-
- Beura SK, Dhapola R, Panigrahi AR et al (2022) Redefining oxidative stress in Alzheimer’s disease: targeting platelet reactive oxygen species for novel therapeutic options. Life Sci 306:120855. https://doi.org/10.1016/J.LFS.2022.120855 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous